How Letybo Works on Wrinkles
Letybo (letibotulinumtoxinA-wlbg) is an injectable botulinum toxin type A that temporarily relaxes specific facial muscles to smooth dynamic wrinkles—those caused by repeated muscle contractions like frowning or squinting.[1] It blocks acetylcholine release at neuromuscular junctions, preventing muscle fibers from contracting and reducing the skin's creasing over time.[2]
What Types of Wrinkles Does It Target?
Letybo treats moderate to severe glabellar lines (frown lines between the eyebrows), lateral canthal lines (crow's feet around the eyes), and forehead lines. These are hyperfunctional wrinkles from expressions, not static ones from aging skin loss.[1][3]
How Is the Treatment Administered?
Doctors inject small doses (typically 20-65 units total, split across sites) directly into targeted muscles using a fine needle. Effects start in 3 days, peak at 14-30 days, and last 3-4 months, requiring repeat sessions for maintenance.[1][4] No anesthesia is needed, but ice or topical numbing helps discomfort.
Why Does It Relax Muscles Without Affecting Others?
The toxin precisely targets injection sites due to its localized action and dilution. It doesn't spread systemically at cosmetic doses, preserving natural expressions elsewhere.[2][5]
What Results Do Patients See?
Clinical trials showed 80-95% of patients had at least a 1-grade improvement in wrinkle severity at day 30, with effects fading gradually.[1] Results look natural, as Letybo has a lower diffusion rate than some competitors, minimizing unintended weakening.[3]
How Does Letybo Compare to Botox or Dysport?
All are botulinum toxin type A but differ in formulation and potency units:
- Letybo: Purified with lower complexing proteins; units aren't interchangeable (1 Letybo unit ≠ 1 Botox unit).[6]
- Botox (onabotulinumtoxinA): Original, higher diffusion for broader effect.
- Dysport (abobotulinumtoxinA): Faster onset but spreads more.
| Aspect | Letybo | Botox | Dysport |
|--------|--------|-------|---------|
| Onset | 3 days | 3-7 days | 2-3 days |
| Duration | 3-4 months | 3-4 months | 3 months |
| Diffusion | Low | Medium | High |
| Units for glabellar lines | 20 | 20 | 50 |
Switching requires dose adjustment by a provider.[6]
Common Side Effects and Risks
Most are mild: injection-site pain, redness, or headache (10-25% of patients). Rare issues include eyelid droop (1-5%) or asymmetry, which resolve in weeks. Avoid if pregnant, breastfeeding, or with neuromuscular disorders.[1][4] Overuse risks muscle weakening or resistance over years.
Who Makes Letybo and When Was It Approved?
Daewoong Pharmaceutical developed it; Hugel Inc. (US partner) got FDA approval in February 2024 for cosmetic use, after Hugel’s Phase 3 trials.[1][7] It's the sixth Botox alternative approved.
[1]: FDA Label for Letybo
[2]: Botulinum Toxin Mechanism - NIH
[3]: Letybo Prescribing Information - Hugel
[4]: Clinical Trial Data - J Drugs Dermatol (2023)
[5]: Toxicity Profile - Aesthetic Surg J (2024)
[6]: Comparative Review - Dermatol Surg (2024)
[7]: FDA Approval Announcement